Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.66 |
| ▸ | CDK6 | Q00534 | 9/20 | 0.66 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.62 |
| ▸ | CCND1 | P24385 | 12/20 | 0.61 |
| ▸ | CCND3 | P30281 | 11/20 | 0.61 |
| ▸ | CCND2 | P30279 | 10/20 | 0.61 |
| ▸ | CDK2 | P24941 | 3/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.61 |
| ▸ | CDK9 | P50750 | 2/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.58 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.58 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.58 |
| ▸ | CCNT2 | O60583 | 1/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.58 |
| ▸ | STK16 | O75716 | 1/20 | 0.58 |
| ▸ | CCNK | O75909 | 1/20 | 0.58 |
| ▸ | PDE5A | O76074 | 1/20 | 0.58 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.58 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29600291 | 1.00 | CDK4 (0.66) | CDK4CDK6CDK12CCND1CCND3 | |
| SCHEMBL28488685 | 0.96 | CDK4 (0.67) | CDK4CDK6CDK12CCND1CCND3 | |
| SCHEMBL2077623 | 0.94 | CDK4 (0.70) | CDK4CDK6CDK12CCND1CCND3 | |
| SCHEMBL4832945 | 0.92 | CDK4 (0.67) | CDK4CDK6CDK12CCND1CCND3 | |
| SCHEMBL20490014 | 0.92 | CDK4 (0.66) | CDK4CDK6CDK12CCND1CCND3 | |
| SCHEMBL4721497 | 0.91 | CDK4 (0.60) | CDK4CDK6CDK12CCND1CCND3 | |
| SCHEMBL30616806 | 0.90 | CDK4 (0.64) | CDK4CDK6CDK12CCND1CCND3 | |
| SCHEMBL16248285 | 0.90 | CDK4 (0.57) | CDK4CDK6CDK12CCND1CCND3 | |
| SCHEMBL27647398 | 0.90 | CDK4 (0.62) | CDK4CDK6CDK12CCND1CCND3 | |
| SCHEMBL4442470 | 0.89 | CDK4 (0.77) | CDK4CDK6CDK12CCND1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214994-A1 | PROCESS FOR THE PREPARATION OF PALBOCICLIB | ALIVUS LIFE SCIENCES LIMITED (IN) | 2025-07-03 | — | — | US | claimed |
| WO-2023194870-A1 | PROCESS FOR THE PREPARATION OF PALBOCICLIB | GLENMARK LIFE SCIENCES LIMITED (IN) | 2023-10-12 | — | — | WO | claimed |
| EP-3431475-B1 | SOLID FORMS OF A SELECTIVE CDK4/6 INHIBITOR | PFIZER (US) | 2021-04-07 | — | — | EP | claimed |
| CN-111686081-A | Pyridine oxide derivative-loaded nano-microsphere and application thereof | 黄泳华 | 2020-09-22 | — | — | CN | claimed |
| CN-111574518-A | Pyridine oxide derivative and composition, preparation method and application thereof | 黄泳华 | 2020-08-25 | — | — | CN | claimed |
| EP-3431475-A1 | SOLID FORMS OF A SELECTIVE CDK4/6 INHIBITOR | Pfizer Inc (US) | 2019-01-23 | — | — | EP | claimed |
| EP-1648889-B1 | ISETHIONATE SALT OF A SELECTIVE CDK4 INHIBITOR | WARNER LAMBERT CO (US) | 2008-10-29 | — | — | EP | claimed |
| US-7345171-B2 | Isethionate salt of a selective CKD4 inhibitor | WARNER-LAMBERT COMPANY LLC (US) | 2008-03-18 | — | — | US | claimed |
| US-20050059670-A1 | 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, which is a preferential cyclin-dependent kinase 4 (CDK4) inhibitor, used for treating inflammation and cell proliferative diseases such as cancer and restenosis | PFIZER INC | 2005-03-17 | — | — | US | claimed |
| US-20250214994-A1 | PROCESS FOR THE PREPARATION OF PALBOCICLIB | ALIVUS LIFE SCIENCES LIMITED (IN) | 2025-07-03 | — | — | US | disclosed |
| US-20250214994-A1 | PROCESS FOR THE PREPARATION OF PALBOCICLIB | ALIVUS LIFE SCIENCES LIMITED (IN) | 2025-07-03 | — | — | US | disclosed |
| US-11858928-B2 | Process for making palbociclib | SYNTHON B.V. (NL) | 2024-01-02 | — | — | US | disclosed |
| US-11858928-B2 | Process for making palbociclib | SYNTHON B.V. (NL) | 2024-01-02 | — | — | US | disclosed |
| EP-4289844-A2 | A PROCESS FOR MAKING PALBOCICLIB | Synthon B.V. (NL) | 2023-12-13 | — | — | EP | disclosed |
| US-7345171-B2 | Isethionate salt of a selective CKD4 inhibitor | WARNER-LAMBERT COMPANY LLC (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345171-B2 | Isethionate salt of a selective CKD4 inhibitor | WARNER-LAMBERT COMPANY LLC (US) | 2008-03-18 | — | — | US | disclosed |
| US-20080021037-A1 | ISETHIONATE SALT OF A SELECTIVE CDK4 INHIBITOR | PFIZER INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021037-A1 | ISETHIONATE SALT OF A SELECTIVE CDK4 INHIBITOR | PFIZER INC. | 2008-01-24 | — | — | US | disclosed |
| US-20050222163-A1 | Combinations of signal transduction inhibitors | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| US-20050059670-A1 | 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, which is a preferential cyclin-dependent kinase 4 (CDK4) inhibitor, used for treating inflammation and cell proliferative diseases such as cancer and restenosis | PFIZER INC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059670-A1 | 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, which is a preferential cyclin-dependent kinase 4 (CDK4) inhibitor, used for treating inflammation and cell proliferative diseases such as cancer and restenosis | CDK4, CDK5, CDK3 | CDK4 1/4885CDK6 11/4885CDK12 60/4885 |
| US-20080021037-A1 | ISETHIONATE SALT OF A SELECTIVE CDK4 INHIBITOR | CDK4, CCNI, CDK3 | CDK4 1/4885CDK6 12/4885CDK12 57/4885 |
| US-20250214994-A1 | PROCESS FOR THE PREPARATION OF PALBOCICLIB | CDK4, CDK2, PDGFRB | CDK4 1/4885CDK6 5/4885CDK12 55/4885 |
| US-20050222163-A1 | Combinations of signal transduction inhibitors | CDK4, CDK3, CDK2 | CDK4 1/4885CDK6 7/4885CDK12 78/4885 |
| US-11858928-B2 | Process for making palbociclib | KRAS, CDK4, FGFR1 | CDK4 2/4885CDK6 37/4885CDK12 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.